Natalie Munk Myriad Genetics Inc (MYGN) insider trading activity

Natalie Munk is Chief Accounting Officer of MYRIAD GENETICS INC. Currently has a direct ownership of 46,129 shares of MYGN, which is worth approximately $409,625. The most recent transaction as insider was on Mar 25, 2025, when has been sold 362 shares (Common Stock) at a price of $9.73 per share, resulting in proceeds of $3,522. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.1K

6.63% 3M change

3.8% 12M change

Total Value Held $409,625

Natalie Munk Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 25 2025	SELL Payment of exercise price or tax liability	$3,522 $9.73 p/Share	362 Reduced 0.78%	46,129 Common Stock
Mar 24 2025	SELL Payment of exercise price or tax liability	$9,800 $9.98 p/Share	982 Reduced 2.07%	46,491 Common Stock
Mar 22 2025	SELL Payment of exercise price or tax liability	$15,645 $10.01 p/Share	1,563 Reduced 3.19%	47,473 Common Stock
Mar 15 2025	SELL Payment of exercise price or tax liability	$6,887 $10.07 p/Share	684 Reduced 1.38%	49,036 Common Stock
Mar 14 2025	SELL Payment of exercise price or tax liability	$8,609 $10.07 p/Share	855 Reduced 1.69%	49,720 Common Stock
Mar 13 2025	BUY Grant, award, or other acquisition	-	4,000 Added 7.33%	50,575 Common Stock
Feb 07 2025	BUY Grant, award, or other acquisition	-	3,316 Added 6.65%	46,575 Common Stock
Sep 21 2024	SELL Payment of exercise price or tax liability	$26,644 $27.64 p/Share	964 Reduced 2.18%	43,259 Common Stock
Aug 25 2024	SELL Payment of exercise price or tax liability	$6,102 $28.12 p/Share	217 Reduced 0.49%	44,223 Common Stock
Apr 06 2024	SELL Payment of exercise price or tax liability	$11,771 $20.26 p/Share	581 Reduced 1.29%	44,440 Common Stock
Mar 25 2024	SELL Payment of exercise price or tax liability	$7,978 $21.98 p/Share	363 Reduced 0.8%	45,021 Common Stock
Mar 24 2024	SELL Payment of exercise price or tax liability	$21,817 $22.24 p/Share	981 Reduced 2.12%	45,384 Common Stock
Mar 22 2024	SELL Payment of exercise price or tax liability	$8,073 $22.24 p/Share	363 Reduced 0.78%	46,365 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	7,500 Added 13.83%	46,728 Common Stock
Sep 21 2023	BUY Grant, award, or other acquisition	-	10,000 Added 20.31%	39,228 Common Stock
Aug 25 2023	SELL Payment of exercise price or tax liability	$3,858 $17.7 p/Share	218 Reduced 0.74%	29,228 Common Stock
Mar 25 2023	SELL Payment of exercise price or tax liability	$8,657 $23.72 p/Share	365 Reduced 1.2%	30,029 Common Stock
Mar 24 2023	SELL Payment of exercise price or tax liability	$23,411 $23.72 p/Share	987 Reduced 3.24%	29,446 Common Stock
Mar 22 2023	SELL Payment of exercise price or tax liability	$8,889 $22.91 p/Share	388 Reduced 1.24%	30,798 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	6,000 Added 16.14%	31,186 Common Stock
Aug 25 2022	SELL Payment of exercise price or tax liability	$5,476 $24.89 p/Share	220 Reduced 0.87%	25,186 Common Stock

Natalie Munk

Chief Accounting Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MYGN shares.

Notify only if

Value

Insider Trading

Get notified when an Myriad Genetics Inc insider buys or sells MYGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to MYRIAD GENETICS INC

Track Activities on MYGN

Account